Abstract:Abstract BACKGROUND Despite making up roughly one quarter of the patients with inflammatory bowel diseases (IBD) in the United States, older adults are an understudied population. Chronic steroid use may be as high as 40% in this population and advanced therapies are often deferred, even though long-term treatment goals are to achieve endoscopic remission utilizing steroid-sparing agents. In order to further explore this, we assessed differences in medication usage between older and younger adults with IBD, stratified by disease activity. METHODS We analyzed surveys from the Crohn’s and Colitis Foundation’s IBD Qorus learning health system for patient visits between 6/1/22 and 10/31/22. Patients were stratified by age (>60 years vs. ≤ 60 years), whether mucosal healing was achieved, and patients’ symptoms (mild or moderate-severe) based on PRO-2 UC and PRO-3 CD scores. Univariable analyses were conducted using Chi-square analysis or Fisher’s exact test where appropriate. RESULTS Overall there were 3,470 patient visits across 35 sites. 31% of the patients were >60 years old, 46.9% were male and 58.6% had Crohn’s disease (Table 1). In our cohort, 51.2% of older adults were treated with advanced therapies, 72.4% were in clinical remission (vs. 62.6% in younger adults, p<0.01), and 51.3% achieved mucosal healing (vs. 46.7% of younger adults, p<0.01). Only 5.7% of older patients had been treated with systemic steroids in the preceding 3 months. Older patients were more likely to be treated with mesalamine (18.9% vs. 12.6%, p<.001) and anti-integrins (15.2% vs. 12.5%, p=.02) but less likely to be treated with anti-IL-12/23 inhibitors (12.6% vs. 15.5%, p=.01). Amongst all patients with active disease, there was no difference in advanced therapy usage regardless of the whether the disease activity was mild or moderate-severe (Table 2). Among older adults not achieving mucosal healing, providers were less likely to optimize current therapy (13.3% vs. 17.3% younger adults, p=.008) or add a new therapy (10% vs. 13% younger adults, p=.02), citing that in 21% of cases they believed a change in therapy would “not lead to meaningful impact” as compared to noting this in only 12% of younger adults (p<.001). CONCLUSION In this real-world, multicenter study, older adults with IBD were more likely to report clinical remission, and were also more likely to achieve endoscopic healing than younger adults. The biggest difference in medication use between the two groups was noted in those with mucosal healing. However, among those not achieving mucosal healing, clinicians were less likely to change therapy for older patients, as they felt it was not likely to have a meaningful impact, even in those with symptoms. Further studies will be needed to better understand these differences in approaches in order to prevent bias in treatment selection. Table 1 Demographics of all patients in the study. Statistically significant differences are noted in bold. * indicates that there were not enough patients to perform statistical analysis. Table 2 Current medication use based on disease activity and patient symptoms. Statistically significant results are noted in bold. * indicates that there were not enough patients to perform statistical analysis.

S1293 Impact of Mild Endoscopic Disease Activity on Short-Term Clinical Outcomes in Older Adults With Inflammatory Bowel Disease

Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease

Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice

Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease

CHRONOLOGICAL AGE INFLUENCES TREATMENT DECISION IN INFLAMMATORY BOWEL DISEASE: AN IBD QORUS COLLABORATIVE STUDY

S1192 Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective Study

S1264 Safety and Effectiveness of Biologic and Small Molecule Therapies in IBD Patients Over the Age of 60

P287 Clinical aspects of late-age Onset Inflammatory Bowel Disease

S1134 A Retrospective Study on the Disease Course of Anorectal Stricture With Terminal Ileal Disease Versus Terminal Ileal Disease Alone in Patients With Crohn's Disease

Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective Trial

Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials

P577 Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

Can we change the natural course of inflammatory bowel disease?

Histologic Activity From Neoterminal Ileal Biopsies in Patients With Crohn's Disease in Endoscopic Remission is Associated With Postoperative Recurrence

Management Considerations for the Older Adult With Inflammatory Bowel Disease

P250 Geriatric impairments associate with mortality and hospitalisations during follow-up in older IBD outpatients

Lower Impact of Disease on Daily Life and Less Fatigue in Patients With Inflammatory Bowel Disease Following a Lifestyle Intervention

S1143 End Ostomy in Crohn's Disease: Insights From the Cleveland Clinic Inflammatory Bowel Disease Ostomy Research Registry

S1152 The Clinical Course of Inflammatory Bowel Disease in Patients Receiving Cancer Therapy

Development and Investigation of a Non-invasive Disease Severity Index for Inflammatory Bowel Disease

Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease